AI Summary
Thinking
Thinking
We reviewed 12 live results for subclinical rejection and narrowed them down to the 3 options that look most worth comparing first.
The options are TruGraf Kidney, Takfa 0.5mg Capsule and Transplant Genomics.
Source: Transplant Genomics
Description
TruGraf Kidney by Transplant Genomics is a non-invasive peripheral blood gene expression biomarker test designed for serial surveillance of kidney transplant recipients with stable renal function. Utilizing microfluidic PCR technology, the diagnostic assay measures differentially expressed genes to assess immune quiescence and rule out silent subclinical acute rejection more than 90 days post-transplant without requiring invasive protocol biopsies.
Best for
Kidney transplant recipients, Transplant clinicians, Serial post-transplant graft health surveillance and Ruling out subclinical acute rejection without biopsy
Rate this product
Source: Phoenix Exim
Description
Takfa 0.5mg Capsule is an oral immunosuppressive prescription medicine containing tacrolimus 0.5mg, marketed by Intas Pharmaceuticals Ltd. and supplied internationally by Phoenix Exim. It functions as a calcineurin inhibitor to reduce immune-system activity and help prevent organ rejection in kidney, liver, and heart transplant recipients.
Best for
Transplant patients and Preventing organ rejection following kidney, liver, or heart transplant
Rate this product
Source: Unknown source
Description
Transplant Genomics provides molecular diagnostic biomarker testing designed for post-transplant surveillance. Its diagnostic solutions include TruGraf Kidney, a non-invasive blood test that measures differentially expressed genes via microfluidic PCR to rule out silent subclinical acute rejection in stable kidney transplant recipients, helping clinicians make informed decisions and reduce unnecessary surveillance tissue biopsies.
Rate this product
| Compare | #1TruGraf Kidney | #2Takfa 0.5mg Capsule | #3Transplant Genomics |
|---|---|---|---|
| Source | Transplant Genomics | Phoenix Exim | Unknown source |
| Description | TruGraf Kidney by Transplant Genomics is a non-invasive peripheral blood gene expression biomarker test designed for serial surveillance of kidney transplant recipients with stable renal function. Utilizing microfluidic PCR technology, the diagnostic assay measures differentially expressed genes to assess immune quiescence and rule out silent subclinical acute rejection more than 90 days post-transplant without requiring invasive protocol biopsies. | Takfa 0.5mg Capsule is an oral immunosuppressive prescription medicine containing tacrolimus 0.5mg, marketed by Intas Pharmaceuticals Ltd. and supplied internationally by Phoenix Exim. It functions as a calcineurin inhibitor to reduce immune-system activity and help prevent organ rejection in kidney, liver, and heart transplant recipients. | Transplant Genomics provides molecular diagnostic biomarker testing designed for post-transplant surveillance. Its diagnostic solutions include TruGraf Kidney, a non-invasive blood test that measures differentially expressed genes via microfluidic PCR to rule out silent subclinical acute rejection in stable kidney transplant recipients, helping clinicians make informed decisions and reduce unnecessary surveillance tissue biopsies. |
| Best for | Kidney transplant recipients, Transplant clinicians, Serial post-transplant graft health surveillance and Ruling out subclinical acute rejection without biopsy | Transplant patients and Preventing organ rejection following kidney, liver, or heart transplant | |
| Action | Transplant Genomics | Phoenix Exim | Transplant Genomics |
| Rate this product |
"TruGraf Kidney from Transplant Genomics."
Note: TopFind AI compiles product and service information for general comparison purposes only.
